Answers are grounded in this paper and cite their sources.
Neuroendovascular devices must reconcile a small delivery profile with sufficient working dimensions, flexibility, force transmission and biological compatibility within fragile, tortuous vessels. Origami-inspired engineering offers a mathematical language for prescribing transitions between compact and functional configurations. Its relevance extends beyond miniaturisation to deployment sequencing, local compliance, surface coverage, payload protection and potentially reversible manipulation. This narrative review examines the evidence for folding architectures in stents and catheter-mounted structures, their relationship to cerebral flow-diverter mechanics, and their possible integration with endovascular micro- and nanorobotics. Existing research establishes geometric and manufacturing feasibility, but does not establish a general safety advantage in human cerebral vessels. Particular distinctions are required between structural origami, compliant or kirigami mechanisms, magnetically actuated particle collectives and molecular DNA origami. These platforms share opportunities for programmed transformation but differ in fabrication, actuation, transport, tracking and biological fate. Potential neurointerventional applications include compact retrieval cages, conformable scaffolds, controlled distal catheter components and locally triggered therapeutic carriers. Principal limitations include finite thickness, friction, geometric incompatibility, snap-through, focal vessel loading, fatigue, thromboembolism, incomplete recovery and uncertain material clearance. An evaluation framework is proposed that follows the entire device life cycle from packaging through navigation, deployment, therapy and retrieval or degradation. Future progress should be judged against clinically meaningful comparators and the coupled constraints of the delivery system, vascular anatomy, haemodynamics and therapeutic objective. Origami-inspired geometry is a credible design strategy for selected neuroendovascular problems; it is neither a guarantee of miniaturisation nor an established route to autonomous intracranial nanorobotic therapy.
No takes yet. Share an insight, caveat, or question.
Prithvijit Chakraborty (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: